• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Update on Breast Cancer Risk Reduction Therapy
Abstract In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prol...
Source: Current Breast Cancer Reports - July 19, 2016 Category: Cancer & Oncology Source Type: research

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news